Please report any queries concerning the funding data grouped in the
sections named
"Externally Awarded"
or
"Internally Disbursed"
(shown on the profile page) to your Research Finance Administrator.
Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php
by entering your department
Please report any queries concerning the student data shown on the
profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
› More
search options
Prof Kerry Chester
UCL Cancer Institute, Paul O'Gorman Building
72 Huntley Street
London
WC1E 6BT
Appointment
- Professor of Molecular Medicine
- Research Department of Oncology
- Cancer Institute
- Faculty of Medical Sciences
Role
UCL Principal Supervisor,UCL Subsidiary Supervisor
Research Groups
See
More
See
Less
Research Themes
Research Summary
Kerry leads the Recombinant Antibody Therapeutics Group at the UCL Cancer Institute. Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with cancer targets. The basic antibody fragment used is the single chain Fv (scFv) and constructs such as scFv fusion proteins with enzymes or albumin are explored. There is a focus on Bench-to-Bedside and the Group has a licensed Production Facility to make antibody-based therapeutics in compliance with Good Manufacturing Practice (GMP). The Cancer Institute offers a unique opportunity for translational work as facilities are available for basic research, pre-clinical testing and Phase I clinical trials.
Academic Background
| 1984 | Doctor of Philosophy | University of London | |
| 1974 | Bachelor of Science (Honours) | University of Salford |
